GANX — Gain Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1819411 ·
Last close
$1.05
Market Cap
$46.75M
52W High
$4.34
52W Low
$0.94
ADV30
688,601
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -3,203,132 | -3,160,408 | 13,231,887 | 11,697,570 | 3,081,231 |
| Jun 2026 | 0 | — | -4,681,652 | -4,675,571 | 15,421,939 | 13,084,144 | 4,129,908 |
| Mar 2026 | 0 | — | -5,353,545 | -5,608,732 | 18,738,464 | 16,539,222 | 4,731,487 |
| Dec 2025 | 0 | — | -4,466,023 | -4,537,581 | 22,818,975 | 20,837,628 | 4,254,227 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,952,455
Investing CF
$0
Financing CF
$25,354,389
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-111,640,310
Inventory
—
Receivables
$1,031,706
ST Investments
—
EBIT TTM
$-19,286,997
Pretax Income TTM
$-19,199,717
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -18,710,702 | -20,161,099 | 22,818,975 | 4,254,227 | 18,564,748 | -18,465,432 |
| Dec 2024 | 0 | -20,350,592 | -20,411,191 | 12,123,884 | 4,784,310 | 7,339,574 | -18,873,827 |
| Dec 2023 | 55,180 | -22,253,133 | -22,267,520 | 18,609,331 | 6,031,107 | 12,578,224 | -18,865,873 |
| Dec 2022 | 140,108 | -17,777,045 | -17,590,738 | 24,099,387 | 5,219,873 | 18,879,514 | -14,692,139 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$-38,573,994
NetIncome TTM
$-20,106,257
OpCashFlow TTM
—
Assets (Latest)
$15,421,939
Forward EPS
$-0.60
Max Pain — expiry 2027-02-19
max pain strike: $1.00 · spot: $1.05 · call oi: 2,305 · put oi: 93
Expected Move to 2027-02-19:
±$0.56
(53.81%) —
implied range
$0.49 –
$1.61
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RFL | Rafael Holdings, Inc. | $46.26M | $0.90 | — |
| HOWL | Werewolf Therapeutics, Inc. | $47.90M | $0.99 | — |
| SPRO | Spero Therapeutics, Inc. | $48.14M | $0.83 | — |
| QUCY | Quantum Cyber N.V. | $48.16M | $0.55 | — |
| PDSB | PDS Biotechnology Corp | $45.19M | $0.81 | — |
News headlines (Yahoo Finance, 1h cache)
Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
2026-11-17 21:15 · Yahoo
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
2026-11-16 16:00 · Yahoo
Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
2026-11-10 12:00 · Yahoo
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
2026-11-05 12:00 · Yahoo
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
2026-10-08 11:00 · Yahoo
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
2026-10-01 13:28 · Yahoo
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
2026-09-29 21:50 · Yahoo
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
2026-09-17 11:00 · Yahoo
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-25 11:00 · Yahoo
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
2026-07-16 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.